This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Herman, T. S. Articles by Teicher, B. A. Search for Related Content PubMed PubMed Citation Articles by Herman, T. S. Articles by Teicher, B. A.

Sequencing of Trimodality Therapy [cis-Diamminedichloroplatinum(II)/Hyperthermia/Radiation] as Determined by Tumor Growth Delay and Tumor Cell Survival in the FSaIIC Fibrosarcoma¹

Joint Center for Radiation Therapy [T. S. H.] and Dana-Farber Cancer Institute [T. S. H., B. A. T.], Boston, Massachusetts 02115

In order to improve local control of tumors over that achievable with local hyperthermia and radiation, we are testing the use of systemic cis-diamminedichloroplatinum(II) (CDDP) in conjunction with the other two modalities. In the FSaIIC fibrosarcoma, growth delay experiments indicated that the use of any two modalities resulted in at least additive effects on growth delay. When the trimodality treatment was tested, the sequence CDDP followed by hyperthermia followed by X-ray produced a growth delay of approximately 25 days which was superior to the growth delay produced by the sequences CDDP, X-ray, and hyperthermia (19 days) and X-ray, CDDP and hyperthermia (14 days). In excision experiments, also performed in the FSaIIC tumor system, we again observed clearly superior cytotoxicity in the sequence CDDP, hyperthermia, and X-rays over the other sequences tested. Our results indicate that scheduling CDDP just prior to heating and following the heat treatment with the radiation fractions results in the best tumor cell kill, probably because this sequence takes maximim advantage of the radiosensitizing properties of the combined heat-CDDP treatment. In addition, the strong cytotoxic interaction between CDDP and hyperthermia is also optimized by this scheduling. We believe these results have significant clinical implications.

¹ This work was supported by grants from the Fuller Fund, New England Deaconess Hospital (T. S. H.), and NIH RO1-CA36508 (B. A. T.).

² To whom requests for reprints should be addressed, at Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115.

Received 11/ 6/87. Revised 1/29/88. Accepted 2/15/88.